Intelligent PTH Compound Administration Systems

Publication ID: 24-11857603_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent PTH Compound Administration Systems,” Published Technical Disclosure No. 24-11857603_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857603_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,603.

Summary of the Inventive Concept

A synergistic system integrating PTH compounds with AI, IoT, blockchain, and nanomaterials to optimize treatment outcomes for hypoparathyroidism patients

Background and Problem Solved

The original patent disclosed PTH compounds with low peak-to-trough ratios, but limitations in administration intervals and dosing optimization hindered treatment effectiveness. This inventive concept addresses these limitations by incorporating advanced technologies to create a more personalized, efficient, and effective treatment system

Detailed Description of the Inventive Concept

The system comprises a PTH compound, a blockchain-based tracking system for monitoring administration intervals, and an AI-powered dosing algorithm for optimizing peak to trough ratios. Additionally, the system may include a nanomaterial-based delivery system, IoT-enabled wearable devices for real-time monitoring, and machine learning models for predicting patient response and personalizing treatment. The AI algorithm integrates patient data, pharmacokinetic profiles, and genomic information to adjust dosing in real-time, ensuring optimal treatment outcomes

Novelty and Inventive Step

The integration of AI, IoT, blockchain, and nanomaterials with PTH compounds creates a novel, non-obvious system that surpasses the original patent's limitations. The inventive step lies in the synergistic combination of these technologies to optimize treatment outcomes, providing a more effective and personalized approach to hypoparathyroidism treatment

Alternative Embodiments and Variations

Alternative embodiments may include different AI algorithms, varying nanomaterial designs, or alternative IoT-enabled devices. The system may also be adapted for other diseases or conditions requiring personalized treatment, expanding the scope of the inventive concept

Potential Commercial Applications and Market

The intelligent PTH compound administration system has significant commercial potential in the pharmaceutical and healthcare industries, offering a more effective and personalized approach to treating hypoparathyroidism. The system may be marketed as a premium product, targeting hospitals, clinics, and healthcare providers seeking to improve patient outcomes and reduce treatment costs

CPC Classifications

SectionClassGroup
A A61 A61K38/29
A A61 A61K9/00
A A61 A61K47/34
A A61 A61K47/60

Original Patent Information

Patent NumberUS 11,857,603
TitlePTH compounds with low peak-to-trough ratios
Assignee(s)ASCENDIS PHARMA BONE DISEASES A/S